Article
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
Bullish
50.8
−100 Bearish
0
+100 Bullish
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
CNBC Top Stories
Published
Mar 25, 2026 · 11:34 am
Article ID
020hj93
Original URL
Open source
Sentiment Signal
Bullish
50.8
−100Neutral+100
More Like This